Tadd Wessel is the founder and Managing Partner of Petrichor. He is also a founder and Managing Partner of Petrichor Scion Therapeutics Management LLC, an affiliate of Petrichor. Tadd has more than 25 years of experience, primarily focused on investing and building companies in the life sciences sectors. Previously, he was a Partner at OrbiMed Advisors where he led the build-out of the structured investment business. Prior to OrbiMed, Tadd was a Vice President at Fortress Investment Group focused on healthcare investments. Tadd began his career in the life sciences investment banking groups at Citigroup and Robertson Stephens. Tadd has served on more than 30 boards, most recently including Aurion Biotech, Cryoport (NASDAQ: CYRX), and ITM. He also serves on the Advisory Board of the AIM at Melanoma Foundation, whose mission is dedicated to finding more effective treatments and, ultimately, the cure for melanoma. As a board member of the International Centers for Precision Oncology (ICPO), he is dedicated to improving access to molecularly targeted precision oncology diagnostics and therapeutics for the benefit of cancer patients worldwide.
